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Mycobacterium avium-M. intracellulare complex (MAC) is the most frequent cause of opportunistic bacterial
infection in patients with AIDS. Previous studies have indicated that liposome-encapsulated aminoglycosides
are highly effective in treating MAC infections in mice. We investigated whether the fluoroquinolone sparfloxacin is effective in treating MAC infection in the murine macrophage-like cell line J774. Sparfloxacin was
encapsulated in the membrane phase of multilamellar liposomes composed of phosphatidylglycerol-phosphatidylcholine-cholesterol (1:1:1 molar ratio). MAC-infected macrophages were treated for either 24 h or 4 days
with free or liposome-encapsulated sparfloxacin. Treatment with free or liposome-encapsulated sparfloxacin (6
mg/ml) for 24 h resulted in the reduction of the growth index to 25 and 30% of that of untreated controls,
respectively. When cultures were treated for 4 days, free sparfloxacin reduced the growth index to 6% of that
of the untreated control, while liposome-encapsulated sparfloxacin reduced it to 8% of that of the control.
against several strains of MAC in vitro (22, 35) and inside
human monocyte-derived macrophages (12, 29, 31). We examined the efficacy of liposome-encapsulated sparfloxacin against
intracellular MAC infection, as a primer for the eventual use of
this formulation in vivo.

Mycobacterium avium-M. intracellulare complex (MAC)
causes serious pulmonary and disseminated infection and is the
most frequent species of bacteria cultured from patients with
AIDS (15, 18, 33, 36). MAC infections contribute substantially
to morbidity and death in patients with AIDS (7, 17, 18). MAC
is resistant to most antituberculosis drugs (14, 16). The drug
susceptibility patterns of MAC isolates from patients with
AIDS differ from those of strains isolated from patients without AIDS (19). An additional problem in the therapy of MAC
infections is that many drugs that are effective against MAC in
vitro are not effective in vivo (25). Four- or five-drug regimens
appear to be necessary to control MAC infections (5, 18, 36).
However, Agins et al. (1) have reported that although multidrug treatment can clear bacteremia, it perhaps does not prolong the survival of patients with disseminated disease. In contrast, Chin et al. (7) have found that patients with MAC
bacteremia who were treated had a longer median survival
time than those who were not.
MAC replicates within macrophages in lung, liver, and
spleen tissues, bone marrow, lymph nodes, and the intestines
and is also found in the blood (2, 18). Since both in vitro and
in vivo studies have shown that liposomes are phagocytosed by
macrophages (8, 9, 23, 30, 32), and because they are naturally
targeted to the liver and spleen, the major organs infected with
MAC, they may be ideal vehicles for directing antibiotics to
sites of infection. In animal models for MAC infection, liposome-encapsulated amikacin (6, 11), gentamicin (6, 21), streptomycin (10, 13), and kanamycin (34) show efficacies higher
than those of the free antibiotics. Liposome-encapsulated amikacin, streptomycin, ciprofloxacin, ofloxacin, clarithromycin,
and azithromycin are also more effective than the unencapsulated drugs against MAC in macrophages (3, 20, 24, 27, 28).
Sparfloxacin has been identified as an effective antibiotic
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MATERIALS AND METHODS
Reagents. Sparfloxacin was a gift from Parke Davis (Ann Arbor, Mich.). Egg
yolk phosphatidylcholine and phosphatidylglycerol derived from phosphatidylcholine by transphosphatidylation were from Avanti Polar Lipids (Alabaster,
Ala.), and cholesterol was from Calbiochem (La Jolla, Calif.). Bovine serum
albumin (BSA), sodium dodecyl sulfate (SDS), NaCl, KCl, sucrose, dimethylsulfoxide (DMSO), ammonium sulfate, and HEPES (N-2-hydroxyethylpiperazineN9-2-ethanesulfonic acid) were obtained from Sigma (St. Louis, Mo.), and Sephadex G-75 was from Pharmacia (Piscataway, N.J.). Solutions were prepared in
distilled water further purified in a Barnstead Nanopure filtration apparatus.
Preparation of liposomes. Since the aqueous solubility limit of sparfloxacin is
very low (0.24 mg/ml, according to the manufacturer’s specifications), it was
initially dissolved together with the phospholipids and cholesterol in chloroform
(CHCl3). Following the evaporation of the solvent and hydration of the dried
lipid in HEPES-buffered saline, sparfloxacin was incorporated in the membrane
phase of the liposomes. Multilamellar liposomes were prepared as follows. Chloroform solutions of phosphatidylglycerol, phosphatidylcholine, cholesterol, and
sparfloxacin were mixed at a 1:1:1:0.4 molar ratio in a glass tube (total phospholipid, 40 to 80 mmol), dried to a thin film on a Büchi rotary evaporator, and then
placed in a vacuum oven at room temperature to remove any residual CHCl3.
The dried film was hydrated with 1 to 2 ml of HEPES buffer (140 mM NaCl, 10
mM KCl, 10 mM HEPES [pH 7.4]) by vortexing under an argon atmosphere. In
some experiments, 132 mM ammonium sulfate was used as the hydration buffer
and the molar ratio of sparfloxacin was reduced to 0.2 in the mixture described
above. Unincorporated sparfloxacin was removed by centrifugation of the liposomes at 10,000 rpm in an Eppendorf centrifuge, equilibrated at 48C, followed by
resuspension in ice-cold HEPES buffer (this process was repeated four times).
The amount of encapsulated sparfloxacin was quantitated by its A304 after an
aliquot of the liposomes was dissolved in a 10-fold excess of methanol. The
encapsulation efficiency of sparfloxacin in these multilamellar liposomes, following three washes in HEPES-buffered saline, was between 45 and 62%. Control
liposomes were prepared similarly, but without the sparfloxacin. The lipid concentration was determined by phosphate assay (4).
Microorganisms. MAC 101, originally provided by C. Inderlied (University of
California, Los Angeles), and MAC SK12, obtained from the Centers for Disease
Control and Prevention, were propagated in beige mice to sustain the virulence
of the bacteria. The spleens of the infected mice were homogenized, and MAC
was cultured on 7H11 plates. Smooth transparent colonies were isolated, grown
in 7H9 broth, and stored in 20% (vol/vol) glycerol in 7H9 in polypropylene vials
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FIG. 1. Treatment of MAC SK12-infected macrophages with free or liposome-encapsulated sparfloxacin. Following infection, the cells were treated for
24 h with free sparfloxacin (Free SP) or sparfloxacin encapsulated in multilamellar liposomes (Liposome SP) (1.5 or 3 mg of sparfloxacin per ml in both
cases). The macrophages were lysed on day 7, and the growth index was determined as described in Materials and Methods. Medium Day 0, growth index of
MAC obtained from macrophages immediately following the infection period;
Medium Day 7, untreated control macrophages; Empty Liposomes, macrophages treated with liposomes containing no drug, at the same lipid concentration as that used for liposome-encapsulated sparfloxacin (3 mg/ml). The data
from a representative experiment are expressed as the means 6 standard deviations (error bars) of growth indices obtained from three wells for each condition.

at 2708C until use. The MICs of sparfloxacin for these strains were determined
by the BACTEC method in Middlebrook 7H12 broth.
Infection and treatment of macrophages. The murine macrophage-like cell
line J774 was maintained in Dulbecco’s modified Eagle medium supplemented
with 10% fetal bovine serum and 50 mg of gentamicin per ml in a 5% CO2
incubator at 378C. MAC was added to the cells at a ratio between 10 and 20 to
1 and incubated for 2 h at 378C. The cells were washed three times with Hanks
balanced salt solution to remove free bacteria and incubated further in Dulbecco’s modified Eagle medium containing only 1% fetal bovine serum to minimize
the growth of the cells. Free or liposome-encapsulated sparfloxacin was added to
the medium for either 24 h or 4 days and then was removed by washing. Seven
days after the initial infection, the macrophages were lysed with 0.5 ml of 0.25%
SDS for 10 min, and after this the lysate was neutralized by the addition of 0.5
ml of BSA. The viable bacteria were quantitated by the radiometric BACTEC
method using Middlebrook 7H12B growth medium. The amount of 14CO2 generated by the metabolism of [14C]palmitic acid within a 24-h period was quantitated and expressed as the growth index. The data are expressed as means 6
standard deviations.

RESULTS
The MICs of sparfloxacin for both MAC strains, SK12 and
101, were 0.5 mg/ml. Higher concentrations of sparfloxacin
were then tested in the MAC-infected macrophage model.
J774 cells infected with MAC SK12 were treated for 24 h with
free or liposome-encapsulated sparfloxacin at concentrations
of 1.5 or 3 mg/ml (Fig. 1). Free sparfloxacin at 1.5 mg/ml had no
effect on the growth of MAC, while at the same concentration
the liposome-encapsulated drug was slightly effective, reducing
the growth index to 80% of that of the untreated control. At 3
mg/ml, free and liposome-encapsulated sparfloxacin reduced
the growth index to 79.6 and 66.2% of that of the untreated
control, respectively. The reduction in growth index by free
drug was not statistically significant, while that caused by lipo-
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FIG. 2. Short-term treatment of MAC 101-infected macrophages with free or
liposome-encapsulated sparfloxacin. Following infection, the cells were treated
for 24 h with free sparfloxacin (Free SP) or sparfloxacin encapsulated in multilamellar liposomes (Liposome SP) (6 mg of sparfloxacin per ml in both cases).
The macrophages were lysed on day 7, and the growth index was determined as
described in Materials and Methods. Medium Day 0, growth index of MAC
obtained from macrophages immediately following the infection period; Medium
Day 7, untreated control macrophages; Empty Liposomes, macrophages treated
with liposomes containing no drug, at the same lipid concentration as that used
for liposome-encapsulated sparfloxacin. The data from a representative experiment are expressed as the means 6 standard deviations (error bars) of growth
indices obtained from three wells for each condition.

somal sparfloxacin was significant (P , 0.05). Treatment of the
macrophages with liposomes without sparfloxacin did not affect the growth of MAC.
Because of the rather limited effect of sparfloxacin on the
SK12 strain even at 3 mg/ml, a concentration well above the
MIC, the experiments with strain 101 were performed with a
6-mg/ml concentration of sparfloxacin. Treatment of infected
macrophages for 24 h with either free or encapsulated sparfloxacin resulted in a pronounced reduction of the growth
index (Fig. 2). The reductions were to 24.5 and 29.7% of the
growth index of the untreated controls in the cases of free
sparfloxacin (P , 0.001) and the liposome-encapsulated drug
(P , 0.001), respectively. The difference between the reductions by the two types of treatment was statistically significant
(P , 0.05). Control treatment of infected macrophages with
DMSO at the same concentration (0.1%) as that used for free
sparfloxacin did not affect the growth index compared with that
of the untreated controls. In this experiment, treatment with
liposomes without sparfloxacin, at the same lipid concentration
as that of drug-containing liposomes, reduced the growth index
slightly. The addition of free sparfloxacin plus liposomes without the drug reduced the growth index to the same level as that
with free sparfloxacin alone.
The effect of extending the treatment time to 4 days was also
investigated (Fig. 3). Free sparfloxacin reduced the growth
index to 6.0% of that of the untreated control, while liposomeencapsulated sparfloxacin reduced it to 8.3% of that of the
control (P , 0.001 for both cases). The small difference be-
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TABLE 1. Viability of J774 macrophages infected with MAC 101
and effect of treatment with free or liposomeencapsulated sparfloxacina
24-h exposure
Treatment

Day 0 control
Day 7 control
Liposome-encapsulated
sparfloxacin
Free sparfloxacin

4-day exposure

GIb (%) Viabilityc (%) GI (%) Viability (%)

100
30.3

100
56
63

100
19.6

100
75
92

18.2

60

7.8

89

a

FIG. 3. Long-term treatment of MAC 101-infected macrophages with free or
liposome-encapsulated sparfloxacin. Following infection, the cells were treated
for 4 days with free sparfloxacin (Free SP) or sparfloxacin encapsulated in
multilamellar liposomes (Liposome SP) (6 mg of sparfloxacin per ml in both
cases). The macrophages were lysed on day 7, and the growth index was determined as described in Materials and Methods. Medium Day 0, growth index of
MAC obtained from macrophages immediately following the infection period;
Medium Day 7, untreated control macrophages; Empty Liposomes, macrophages treated with liposomes containing no drug, at the same lipid concentration as that used for liposome-encapsulated sparfloxacin; DMSO Control, cells
treated with the same concentration of DMSO as in the free sparfloxacin wells,
because of the dilution of the stock sparfloxacin dissolved in DMSO. The data
from a representative experiment are expressed as the means 6 standard deviations (error bars) of growth indices obtained from three wells for each condition.

tween the reductions by the two treatments was statistically
significant (P 5 0.001). The effects on the growth index of
DMSO and liposomes without sparfloxacin were minimal.
Treatment of the infected cells with empty (drug-free) liposomes plus free sparfloxacin produced the same reduction in
the growth index as did free sparfloxacin. The effect of sparfloxacin treatment of MAC-infected macrophages on the viability of the macrophages was also investigated (Table 1). In an
experiment involving a 24-h treatment period, the viability of
cells treated with free or liposomal sparfloxacin was slightly
higher than that of untreated controls at the end of 7 days of
incubation (Table 1). The difference in viability between untreated controls and the treated macrophages was particularly
apparent in an experiment involving a treatment period of 4
days (Table 1). This observation suggests that the treatment of
the infected macrophages, and the resulting decrease in the
growth index of the MAC, reduced the toxicity caused by the
intracellular MAC bacilli.
DISCUSSION
Our results indicate that free and liposome-encapsulated
sparfloxacin have similar effects on the growth of intracellular
MAC, particularly at the higher drug concentrations used. This
observation is in contrast to our previous results with ciprofloxacin, streptomycin, and amikacin, indicating that the lipo-

some-encapsulated drugs were more effective than the free
drug against MAC inside murine peritoneal or human monocyte-derived macrophages (3, 20, 24). Thus, it is likely that both
free sparfloxacin and encapsulated sparfloxacin are taken up
by the cells and that they localize to similar extents inside
intracellular vacuoles containing MAC. This is expected on the
basis of the lipophilic nature of the drug. The slightly greater
anti-MAC effect of liposomal sparfloxacin at the lowest concentration used, compared with that of the free antibiotic (Fig.
1), could be the result of a greater accumulation and availability of the drug in the compartments containing MAC. The
enhanced uptake of liposome-encapsulated antibiotics by J774
macrophages compared with that of the free drug was demonstrated in the case of another fluoroquinolone antibiotic, ciprofloxacin, encapsulated in the aqueous phase of liposomes
composed of distearoylphosphatidylglycerol-distearoylphosphatidylcholine-cholesterol (1:1:1) (27). Another antibiotic,
azithromycin, encapsulated in the membrane phase of such
liposomes showed enhanced efficacy against MAC inside J774
macrophages compared with the free drug, particularly at high
molar ratios of distearoylphosphatidylglycerol to distearoylphosphatidylcholine (27). In the present study, however, sparfloxacin encapsulated in the membrane phase of similar liposomes (composed of analogs of the phospholipids used
for azithromycin [see above]) did not show an enhancement in
efficacy. The lack of enhancement in the case of liposomeencapsulated sparfloxacin is most likely due to the efficient
uptake of the free drug by the infected macrophages, thereby
obviating the dependence on liposome-mediated uptake (Fig.
1).
The observation that the anti-MAC effect of liposome-encapsulated sparfloxacin is similar to that of the free antibiotic
is in apparent contradiction to results obtained by directly
incubating the liposomes with MAC in broth (26). In the study
by Mehta et al. (26), the MICs of liposomal sparfloxacin at
which 50 and 90% of the isolates were inhibited were four
times higher than those of the free antibiotic. The ability of
liposomes to deliver encapsulated antibiotics to MAC bacteria
most likely depends on the microenvironment of both the
MAC and the liposomes, as well as their local concentration.
In macrophages, liposomes deliver their contents locally inside
endosomes or in MAC-containing phagosomes, while in broth,
the contents are diluted into the test tube.
Although liposome-encapsulated aminoglycosides show a
modest increase in efficacy against MAC in macrophages in
culture (3, 20, 24), they are effective at much lower doses in
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Infected cells were treated for either 24 h or 4 days with free or liposomeencapsulated sparfloxacin at a concentration of 6 mg/ml.
b
Growth index, given as the percentage of the growth index of day 7 controls.
The growth index was determined by lysing the macrophages after 7 days in
culture.
c
The viability was determined by trypan blue exclusion. For each condition,
300 cells were counted.
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vivo than that required for the free drug (10, 11, 13). Our
results indicate that free and liposome-encapsulated sparfloxacin are about equally effective against MAC in macrophages in
culture. In analogy with the aminoglycosides, it is likely that
liposome-encapsulated sparfloxacin will have an enhanced effect against MAC infection in vivo because of its ability to
localize in the mononuclear phagocyte (reticuloendothelial)
system. Nevertheless, additional factors, such as the stability of
sparfloxacin in liposomes during circulation in the bloodstream, can influence the efficacy of liposomal sparfloxacin in
vivo.
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